- Screening
- Baseline
- In the process of the treatment
- At the end of the treatment
- Follow-up 1
- Follow-up 2
- Follow-up 3
- Management system of participants
- Speciman management system
- Data management system
- ADR/ADE management system
- Madicine management system
- Instruments management system
- SOPs
- Research team
- Design, Methods
- Metabolic and endocrine data
1.Screening
1.1.Management for Progress
1.2.Inclusion Criteria
1.3.Exclusion Criteria
2.Baseline
- Management of the progress
- General information
- Physical examination
- Blood Routine Tests
- Metabolic and endocrine data
- Serum lipid
- Inflammatory marks
- Serum Liver Function Tests
- HBV Markers Test
- Renel Function Test
- Heat Function Examination
- Blood Cell Morphology
- Image Examinations
- Nervous System Examination
- Lung Function Examination
- Blood Gas Analysis
- Physical Ability Examination
- Health Relative Quality of Life
2.1.Management of the progress
2.2.General information
|
Drink tea | No
|
|
Hyperuricemia | No
|
|
Hyperlipemia | Yes
|
|
Coronary heart disease | Yes
|
|
Hypertension | No
|
|
duration of diabetes | 4 年 |
|
history of diabetes | Yes
|
|
Alcoholic | No
|
|
Smoking | Yes
|
|
Age | 72 |
|
Sex | 男 |
|
ID | 2 |
2.3.Physical examination
|
Weight | 59.1 Kg |
|
Height | 159 cm |
|
Heart rate | 93 bpm |
|
Diastolic pressure | 90 mmHg |
|
Systolic pressure | 137 mmHg |
2.4.Blood Routine Tests
|
Blood routine examination | 正常 |
2.5.Metabolic and endocrine data
|
Postprandial blood glucose (PBG) | 10.02 mmol/l |
|
Fasting blood-glucose (FBG) | 4.84 mmol/l |
|
Glycated hemoglobin | 7.8 % |
2.6.Serum lipid
2.7.Inflammatory marks
2.8.Serum Liver Function Tests
|
Glutamic oxalacetic transaminase | 50.6 u/l |
|
Glutamic-pyruvic transaminase | 105.5 u/l |
2.9.HBV Markers Test
2.10.Renel Function Test
|
Uric acid | 307.9 umol/l |
|
Creatinine | 309 umol/l |
|
Urea nitrogen | 11.25 mmol/l |
2.11.Heat Function Examination
2.12.Blood Cell Morphology
2.13.Image Examinations
2.14.Nervous System Examination
2.15.Lung Function Examination
2.16.Blood Gas Analysis
2.17.Physical Ability Examination
2.18.Health Relative Quality of Life
4.At the end of the treatment
- Management for Progress
- Physical examination
- Blood Routine Tests
- Urine and Stool Routine Tests
- Serum Electrolytes Tests
- Liver Function Tests
- HBV Markers Test
- Renel Function Test
- Heat Function Examination
- Image Examinations
- Blood Cell Morphology
- Nervous System Examination
- Lung Function Examination
- Blood Gas Analysis
- Physical Sbility Examination
- Health Relative Quality of Life
4.1.Management for Progress
4.2.Physical examination
4.3.Blood Routine Tests
4.4.Urine and Stool Routine Tests
4.5.Serum Electrolytes Tests
4.6.Liver Function Tests
4.7.HBV Markers Test
4.8.Renel Function Test
4.9.Heat Function Examination
4.10.Image Examinations
4.11.Blood Cell Morphology
4.12.Nervous System Examination
4.13.Lung Function Examination
4.14.Blood Gas Analysis
4.15.Physical Sbility Examination
4.16.Health Relative Quality of Life
6.Follow-up 2
7.Follow-up 3
8.Management system of participants
9.Speciman management system
10.Data management system
11.ADR/ADE management system
12.Madicine management system
13.Instruments management system
14.SOPs
14.1.Treatment SOP
14.2.Nursing SOP
14.3.Specimen collection SOP
2.19.Metabolic and endocrine data